CN1129428C - 内皮素受体拮抗剂 - Google Patents
内皮素受体拮抗剂 Download PDFInfo
- Publication number
- CN1129428C CN1129428C CN94192388A CN94192388A CN1129428C CN 1129428 C CN1129428 C CN 1129428C CN 94192388 A CN94192388 A CN 94192388A CN 94192388 A CN94192388 A CN 94192388A CN 1129428 C CN1129428 C CN 1129428C
- Authority
- CN
- China
- Prior art keywords
- hydrogen
- alkyl
- formula
- compound
- indan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6681893A | 1993-04-27 | 1993-04-27 | |
| US08/066,818 | 1993-04-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1124923A CN1124923A (zh) | 1996-06-19 |
| CN1129428C true CN1129428C (zh) | 2003-12-03 |
Family
ID=22071916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94192388A Expired - Fee Related CN1129428C (zh) | 1993-04-27 | 1994-04-26 | 内皮素受体拮抗剂 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0699069B9 (enExample) |
| JP (1) | JP3346571B2 (enExample) |
| KR (1) | KR100331667B1 (enExample) |
| CN (1) | CN1129428C (enExample) |
| AP (1) | AP573A (enExample) |
| AT (1) | ATE213156T1 (enExample) |
| AU (1) | AU682038B2 (enExample) |
| BR (1) | BR9406572A (enExample) |
| CA (1) | CA2160914A1 (enExample) |
| CZ (1) | CZ291189B6 (enExample) |
| DE (1) | DE69429861T2 (enExample) |
| DK (1) | DK0699069T3 (enExample) |
| DZ (1) | DZ1773A1 (enExample) |
| ES (1) | ES2172535T3 (enExample) |
| FI (1) | FI955103A7 (enExample) |
| HU (2) | HU9503067D0 (enExample) |
| IL (1) | IL109443A0 (enExample) |
| MA (1) | MA23172A1 (enExample) |
| NO (1) | NO313754B1 (enExample) |
| NZ (1) | NZ266314A (enExample) |
| PL (1) | PL175392B1 (enExample) |
| PT (1) | PT699069E (enExample) |
| RU (1) | RU2130920C1 (enExample) |
| SG (1) | SG49667A1 (enExample) |
| SI (1) | SI9400195B (enExample) |
| SK (1) | SK130595A3 (enExample) |
| TW (1) | TW330204B (enExample) |
| WO (1) | WO1994025013A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075037A (en) * | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| JPH10501812A (ja) * | 1994-06-20 | 1998-02-17 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗薬 |
| WO1996020193A1 (en) * | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | Compounds and methods |
| AU7677496A (en) * | 1995-11-08 | 1997-05-29 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| US6162932A (en) * | 1995-11-08 | 2000-12-19 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| US6080862A (en) * | 1995-11-08 | 2000-06-27 | Smithkline Beecham Corporation | Stereoselective synthesis of endothelin receptor antagonists |
| ZA969363B (en) * | 1995-11-08 | 1997-11-18 | Smithkline Beecham Corp | An improved process for preparing aromatic ring-fused cyclopentane derivatives. |
| US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| IL126175A (en) | 1996-04-04 | 2003-05-29 | Banyu Pharma Co Ltd | Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists |
| US5932553A (en) | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| AU3867997A (en) | 1996-08-27 | 1998-03-19 | Shionogi & Co., Ltd. | Chromene-3-carboxylate derivatives |
| US5929106A (en) * | 1997-10-27 | 1999-07-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US6025328A (en) | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
| JP2002511442A (ja) * | 1998-04-09 | 2002-04-16 | メルク エンド カムパニー インコーポレーテッド | ホスフェート介在の環化 |
| AR022228A1 (es) | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| NZ586285A (en) | 2004-03-17 | 2011-12-22 | Novartis Ag | Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X) |
| US7423176B2 (en) | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| WO2006066748A1 (en) | 2004-12-21 | 2006-06-29 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof as 5-ht antagonists |
| US20100040666A1 (en) * | 2005-06-24 | 2010-02-18 | Hiroshi Azuma | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent |
| JP4989648B2 (ja) | 2005-08-03 | 2012-08-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗癌剤として有用なイルジン類似体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737455A (en) * | 1971-01-21 | 1973-06-05 | Merck & Co Inc | Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof |
| FI942059A7 (fi) * | 1991-11-05 | 1994-07-04 | Smithkline Beecham Corp | Endoteliinireseptoreiden antagonisteja |
-
1994
- 1994-04-26 AP APAP/P/1994/000636A patent/AP573A/en active
- 1994-04-26 WO PCT/US1994/004603 patent/WO1994025013A1/en not_active Ceased
- 1994-04-26 KR KR1019950704682A patent/KR100331667B1/ko not_active Expired - Fee Related
- 1994-04-26 FI FI955103A patent/FI955103A7/fi not_active Application Discontinuation
- 1994-04-26 AT AT94915903T patent/ATE213156T1/de not_active IP Right Cessation
- 1994-04-26 HU HU9503067A patent/HU9503067D0/hu unknown
- 1994-04-26 JP JP52449694A patent/JP3346571B2/ja not_active Expired - Fee Related
- 1994-04-26 CZ CZ19952835A patent/CZ291189B6/cs not_active IP Right Cessation
- 1994-04-26 SG SG1996003492A patent/SG49667A1/en unknown
- 1994-04-26 SK SK1305-95A patent/SK130595A3/sk unknown
- 1994-04-26 SI SI9400195A patent/SI9400195B/sl not_active IP Right Cessation
- 1994-04-26 RU RU95122388A patent/RU2130920C1/ru active
- 1994-04-26 DK DK94915903T patent/DK0699069T3/da active
- 1994-04-26 EP EP94915903A patent/EP0699069B9/en not_active Expired - Lifetime
- 1994-04-26 AU AU67750/94A patent/AU682038B2/en not_active Ceased
- 1994-04-26 IL IL10944394A patent/IL109443A0/xx unknown
- 1994-04-26 ES ES94915903T patent/ES2172535T3/es not_active Expired - Lifetime
- 1994-04-26 PL PL94311272A patent/PL175392B1/pl unknown
- 1994-04-26 MA MA23478A patent/MA23172A1/fr unknown
- 1994-04-26 CN CN94192388A patent/CN1129428C/zh not_active Expired - Fee Related
- 1994-04-26 PT PT94915903T patent/PT699069E/pt unknown
- 1994-04-26 BR BR9406572A patent/BR9406572A/pt not_active Application Discontinuation
- 1994-04-26 CA CA002160914A patent/CA2160914A1/en not_active Abandoned
- 1994-04-26 HU HU9501931A patent/HUT73763A/hu unknown
- 1994-04-26 NZ NZ266314A patent/NZ266314A/xx not_active IP Right Cessation
- 1994-04-26 DE DE69429861T patent/DE69429861T2/de not_active Expired - Fee Related
- 1994-04-26 DZ DZ940038A patent/DZ1773A1/fr active
- 1994-07-01 TW TW083106015A patent/TW330204B/zh not_active IP Right Cessation
-
1995
- 1995-10-26 NO NO19954291A patent/NO313754B1/no unknown
Non-Patent Citations (1)
| Title |
|---|
| THECHEMICALSOCIETYOFJAPANVOL.59NOL.11 1986-11-01 KIMIAKI,YAMAMURA,FORMATION,OF,2-SUBSTITUED,1,3-DIPHENYLINDENES,BY,AN,N-BROMOSUCCINIMIDE,PROMPTED,DEH * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1129428C (zh) | 内皮素受体拮抗剂 | |
| CN1034569C (zh) | Et(endothelin)受体拮抗物 | |
| CN1088581A (zh) | 内皮素受体拮抗剂 | |
| CN1096513A (zh) | 内皮素受体拮抗剂 | |
| CN1203070C (zh) | 凝血酶受体拮抗药 | |
| CN1365359A (zh) | 苯并呋喃哌嗪和苯并呋喃基高哌嗪:血清素激动剂 | |
| CN1289496C (zh) | 新的帕罗西汀盐酸盐无水合物的制备方法 | |
| CN1151130C (zh) | 神经保护的3-(哌啶基-1)-苯并二氢吡喃-4,7-二醇和1-(4-氢化苯基)-2-(哌啶基-1)链烷醇衍生物 | |
| CN1159325A (zh) | 帕金森氏综合症的协同治疗 | |
| CN1149870A (zh) | 具有促皮质激素释放因子拮抗剂活性的取代的吡唑 | |
| CN1173974C (zh) | 作为p物质拮抗剂的哌啶基氨基甲基三氟甲基环醚化合物 | |
| CN1117966A (zh) | 联苯基衍生物 | |
| CN1053607A (zh) | 用于治疗aids的人体免疫缺乏病毒蛋白酶的抑制剂 | |
| CN1133040A (zh) | 作为雌激素激动剂的苯并噻吩及其有关化合物 | |
| CN1049336C (zh) | 异恶唑衍生物在制备治疗肠应激综合征的组合物中的用途 | |
| CN1290258A (zh) | 具有5-羟色胺1a受体活性的芳基哌嗪类化合物 | |
| CN1558905A (zh) | 茚满乙酸衍生物及其作为药物、中间体的用途以及制备方法 | |
| CN1290265A (zh) | 凝血酶受体拮抗剂 | |
| CN1870999A (zh) | 炔烃ⅰ | |
| CN85107496A (zh) | 制备四氢化萘衍生物的方法 | |
| CN1024663C (zh) | 治疗气喘用的取代的四氢化萘类化合物的制备方法 | |
| CN1407982A (zh) | 血清素能苯并呋喃 | |
| CN1228082A (zh) | 双吲哚基马来酰亚胺的合成 | |
| CN1085209C (zh) | 5,11-二氢二苯并[b,e][1,4]氧氮杂䓬衍生物以及含该衍生物的医药组合物 | |
| CN1196680A (zh) | 皮内素受体拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |